Sycamore Labs | $65,000,000 | (Mar 31, 2026)
Deccan AI | $25,000,000 | (Mar 31, 2026)
Stedi | $50,000,000 | (Mar 31, 2026)
Certified by Founder
Lodge
LTZ Therapeutics
start up
United States
- Redwood City, California
- 01/06/2023
- Pre Series A
- $10,000,000
LTZ Therapeutics is an immunotherapy-focused biotech company pursing the development of novel therapies to improve clinical outcomes in patients with cancer and other diseases with an unmet clinical need. With main operations in Redwood City, California and Shenzhen, China as well as a team in Heidelberg, Germany, LTZ is dedicated to developing immunotherapies capable of overcoming resistance and boosting anti-tumor immunity based on reverse translational science and emerging biology of tumor microenvironment.
- Industry Biotechnology Research
- Website http://www.ltztherapeutics.com/
- LinkedIn https://www.linkedin.com/company/ltz-therapeutics/
OpenBox AI | $5,000,000 | (Mar 31, 2026)
Qodo | $70,000,000 | (Mar 31, 2026)
Starcloud | $170,000,000 | (Mar 31, 2026)
Valinor(1) | $25,000,000 | (Mar 31, 2026)
Mars Men | $27,500,000 | (Mar 31, 2026)
Scalvy | $13,900,000 | (Mar 27, 2026)
SIGMAS | $1,000,000 | (Mar 27, 2026)
CurrentClient | $1,250,000 | (Mar 27, 2026)
VITL | $7,500,000 | (Mar 27, 2026)